Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan

References

• European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
   PubMed Web of Science ®Google Scholar
• Higuchi M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis 2002;55:69-77
   PubMed Web of Science ®Google Scholar
• Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010;53:39-43
   PubMed Web of Science ®Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61:S45-S57
   PubMedGoogle Scholar
• Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296-305
   PubMedGoogle Scholar
• Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-S46
   PubMed Web of Science ®Google Scholar
• Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2007;37:676-91
   PubMed Web of Science ®Google Scholar
• Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health 2012;15:S65-S71
   PubMed Web of Science ®Google Scholar
• Toyokawai S, Kobayashi Y, Ohmori M. Refined method for estimating medical expenditures for liver disease using the patient survey and claim data in Japan. Nihon Koshu Eisei Zasshi 2005;52:957-61
   PubMedGoogle Scholar
• Koh C, Heller T, Haynes-Williams V, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther 2013;37:887-94
   PubMed Web of Science ®Google Scholar
• Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-16 e1
   PubMed Web of Science ®Google Scholar
• Kwo P, Lacerda M. Next generation direct-acting antiviral agents for hepatitis C treatment. N A J Med Sci 2014;7:23-32
   Google Scholar
• Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-9
   PubMed Web of Science ®Google Scholar
• Desmond CP, Roberts SK, Dudley F, et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006;13:311-15
   PubMed Web of Science ®Google Scholar
• Asahina Y, Izumi N, Hiromitsu K, et al. JSH Guidelines for the Management of Hepatitis C Virus Infection: a 2016 update for genotype 1 and 2. Hepatol Res 2016;46:129-65
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Care Excellence. Telaprevir for the treatment of genotype 1 chronic hepatitis C. London: National Institute of Health and Care Excellence; 2012. http://www.nice.org.uk/guidance/ta252. Accessed December 23, 2015
   Google Scholar
• McEwan P, Ward T, Webster S, et al. Estimating the long-term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult-to-treat Japanese patients chronically infected with Hepatitis C Genotype 1b. Value Health Regional Issues 2014;3:136-45
   PubMedGoogle Scholar
• National Institute of Health and Care Excellence. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C. London: National Institute of Health and Care Excellence; 2015. http://www.nice.org.uk/guidance/ta331. Accessed December 23, 2015
   Google Scholar
• Park C, Jiang S, Lawson KA. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther 2014;39:14-24
   PubMed Web of Science ®Google Scholar
• Asahina Y, Hayashi N, Izumi N, et al. JSH Guidelines for the management of hepatitis c virus infection: a 2014 update for Genotype 1. Hepatol Res 2014;44:59-70
   Web of Science ®Google Scholar
• McEwan P, Ward T, Webster S, et al. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res 2016;46:423-33
   PubMed Web of Science ®Google Scholar
• Yoshimi S, Ochi H, Murakami E, et al. Rapid, sensitive, and accurate evaluation of drug resistant mutant (NS5A-Y93H) strain frequency in genotype 1b HCV by invader assay. PLoS One 2015;10:e0130022
   Google Scholar
• Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015;62:1037-46
   PubMed Web of Science ®Google Scholar
• Fukuda T, Shiroiwa T, Ikeda S, et al. Guideline for economic evaluation of healthcare technologies in Japan. J Natl Inst Public Health, 62:2013 (Japanese only)
   Google Scholar
• Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15:i-xii, 1–210
   PubMed Web of Science ®Google Scholar
• Ishida H, Yotsuyanagi H. Examination of the cost-effectiveness of the standard of care for chronic HCV treatment. Research on health-economics of various initiatives related to viral liver diseases, Ministry of Health, Labour and Welfare, Japan (PI: Hirao T) 2014;127-192 (Japanese Only). http://mhlw-grants.niph.go.jp/niph/search/Download.do?nendo=2013&jigyoId=135013&bunkenNo=201333004A&pdf=201333004A0005.pdf. Accessed January 6, 2016
   Google Scholar
• Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Long–term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol. 2012;27:291-9.
   PubMed Web of Science ®Google Scholar
• Ishida K, Imai H, Ogasawara K, et al. Cost-utility of living donor liver transplantation in a single Japanese center. Hepatogastroenterology 2006;53:588-91
   PubMed Web of Science ®Google Scholar
• Suga M, et al. Development of the fundamental model for HCV. Research on health-economics of various initiatives related to viral liver diseases, Ministry of Health, Labour and Welfare, Japan (PI: Hirao T), 2014;76-95 (Japanese Only). http://mhlw-grants.niph.go.jp/niph/search/Download.do?nendo=2013&jigyoId=135013&bunkenNo=201333004A&pdf=201333004A0004.pdf. Accessed January 6, 2016
   Google Scholar
• Tanaka J, Kumada H, Ikeda K, et al. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 2003;70:378-86
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-81
   PubMed Web of Science ®Google Scholar
• Brady B, Sieber U, Sroczynski G, et al. Pegylated Interferon combined with ribavirin for chronic hepatitis C virus infection: an economic evaluation [Technology Report No. 82]. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health (CADTH); 2007
   Google Scholar
• Ministry of Health Labour and Welfare. Abridged Life Tables for Japan 2013. Statistics and Information Department. Minister's Secretariat. Government of Japan: Japan, 2016. http://www.mhlw.go.jp/english/database/db–hw/lifetb13/index.html. Accessed January 6, 2016
   Google Scholar
• Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014;59:2083-91
   PubMed Web of Science ®Google Scholar
• BMS KK, AbbVie GK, Gilead Sciences KK, Interview Form available from PMDA website (in Japanese only). Daklinza Interview Form: http://www.info.pmda.go.jp/go/interview/1/670605_6250040F1020_1_005_1F. Viekirax Interview Form: http://www.info.pmda.go.jp/go/interview/1/112130_62501A2F1027_1_1F. Harvoni Interview Form: http://www.info.pmda.go.jp/go/interview/1/230867_62501A1F1022_1_001_1F.pdf. 2015. Japan. Accessed January 6, 2016
   Google Scholar
• Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15:645-53
   PubMed Web of Science ®Google Scholar
• AbbVie GK. Data on file. GIFT-I Clinical study report. Japan. 2015
   Google Scholar
• Ministry of Health Labour and Welfare. Japanese National Health Insurance drug price list, effective April 2016. Japan: Ministry of Health Labour and Welfare; 2016. http://www.mhlw.go.jp/topics/2014/03/tp0305–01.html (Japanese only). Accessed March 4, 2016
   Google Scholar
• Fukuda T, Shiroiwa T, Ikeda S, et al. Guideline for economic evaluation of healthcare technologies in Japan. J Natl Inst Public Health 2013;62:625-40
   Google Scholar
• Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Making 2003;23:341-50
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness–to–pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37
   PubMed Web of Science ®Google Scholar
• AbbVie GK Data on file. Japan. 2015
   Google Scholar
• Kuwabara H, Westerhout K, Treur M, et al. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naive chronic hepatitis C genotype 1 patients in Japan. J Med Econ 2015;18:502-11
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, et al. Estimation of stagespecific fibrosis progression rates in chronic hepatitis C virus infection: a metaanalysis and metaregression. Hepatology 2008;48:418-31
   PubMed Web of Science ®Google Scholar
• Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35
   PubMed Web of Science ®Google Scholar
• Seeff LB. The history of the “natural history” of hepatitis C (1968–2009). Liver Int 2009;29(1 Suppl):89-99
   PubMed Web of Science ®Google Scholar
• Johnson S, Parise H, Virabhak S, et al. Percent of subjects experiencing liver morbidity over a lifetime horizon with Abbvie 3D (ABT-450/Ritonavir/Ombitasvir And Dasabuvir) versus no treatment. Presented at: European Association for the Study of the Liver (EASL) 50th Annual Meeting, Vienna, Austria, April, 2015
   Google Scholar
• Saab S, Parisé H, Virabhak S, et al. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ 2016:1-11, doi:10.1080/13696998.2016.1176030
   Web of Science ®Google Scholar
• Bristol-Myers Squibb. Report of early post marketing phase vigilance of daklinza/sunvepra. Japan :Bristol-Myers Squibb; 2015. https://file.bmshealthcare.jp/renewal/pdf/phdasu/development/05.pdf (Japanese only). Accessed May 31, 2016
   Google Scholar
• Gilead Sciences Ltd. Report of early post marketing phase vigilance of harvoni. Japan: Gilead Sciences Ltd; 2016. https://www.harvoni.jp/∼/media/files/japan/japan-gilead/pdf/20160513/hvn_post_marketing_surveillance_final_report.pdf?la=ja-jp (Japanese only). Accessed May 31, 2016
   Google Scholar
• AbbVie GK. Report of early post marketing phase vigilance of viekirax. Japan. 2016. https://abbvie-channel.com/contents/contents/download.aspx?file=pdf/viekirax/report05.pdf (Japanese only). Accessed May 31, 2016
   Google Scholar
• Fujiwara Y. Evolution of frameworks for expediting access to new drugs in Japan. Nat Rev Drug Discov 2016;15:293-4
   PubMed Web of Science ®Google Scholar